Sharemaestro Newsreel

Gilead wins appeals court ruling against overseas drug imports

A federal appeals court has upheld a preliminary injunction preventing companies from importing international versions of Gilead's HIV drug Biktarvy into the U.S. and distributing them via employer health plans. The court ruled that the overseas versions materially differ from FDA-regulated U.S. versions, highlighting …

A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40

This article provides a quick overview of analyst ratings for Kura Oncology (KURA.US), noting a forecast price range of $23 to $40. It indicates that the company is currently receiving a 'Buy' rating from analysts, reflecting positive sentiment. The information is presented as a …

This Analyst Believes Eton Pharma’s Raised Guidance Is ‘Conservative’ – ETON Stock Heads For Best Ever Day

Eton Pharmaceuticals (ETON) shares surged 40% to an all-time high after better-than-expected Q2 results, driven by the successful relaunch of Hemangeol. The company raised its full-year 2026 revenue guidance to over $145 million and adjusted EBITDA margin to at least 35%. Analysts from B. …

Novavax Inc. stock underperforms Friday when compared to competitors

Novavax Inc. (NVAX) shares dropped 1.11% on Friday, closing at $8.05, despite a three-day winning streak being snapped. This underperformance occurred on a negative trading day for the broader market, with both the NASDAQ Composite and Dow Jones Industrial Average also experiencing declines.

Aspire BioPharma, Inc. (NASDAQ: ASBP) Share Price, ASBP Stock News, ASBP Share Price & Updates

Molina Healthcare Inc. stock outperforms competitors on strong trading day

Molina Healthcare Inc. (MOH) stock rose by 3.27% to $212.43 on a generally down day for the market, outperforming both the S&P 500 and Dow Jones Industrial Average. The company's stock closed 13.25% below its 52-week high achieved in July.

VistaGen Therapeutics earnings missed by $0.05, revenue topped estimates

Microcaps TOON, IGC, SURG, MDXH to Watch Now as Earnings, AI and Biotech Catalysts Build

VivoSim Labs (NASDAQ: VIVS) Emerges in Drug Toxicity Market as Revenue Growth Guidance Tops 500% – Plus More In Focus

August 2026's Promising Penny Stocks

This article highlights three promising penny stocks for August 2026: Nephros (NEPH), Siebert Financial (SIEB), and Douglas Elliman (DOUG). It examines their financial health, recent performance, and strategic initiatives, noting that these companies offer potential for growth despite being smaller or newer entities. The …

Insulet Corp. stock outperforms competitors despite losses on the day

Insulet Corp. (PODD) stock fell by 2.12% to $143.34 on Friday, breaking a six-day winning streak, despite a broader market decline with the S&P 500 and Dow Jones also experiencing losses. The company's stock still managed to outperform its competitors, even with the daily …

Align Technology Inc. stock outperforms competitors on strong trading day

Align Technology Inc. (ALGN) saw its stock rise by 2.90% to $181.31, outperforming a generally down market where both the S&P 500 Index and Dow Jones Industrial Average experienced slight declines. This marked the third consecutive day of gains for the company's stock.

Oscar Health Inc Stock (OSCR) Moved Up by 7.22% on Aug 14: What Investors Need To Know

Relmada Therapeutics (RLMD) gains 7.0% shareholder position from Squadron funds

Investment entities affiliated with Squadron Capital Management LLC have reported a beneficial ownership of 7.0% in Relmada Therapeutics, Inc. This stake, amounting to 7,350,000 shares, is held by Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank, based on shares …

Biomea Fusion (NASDAQ:BMEA) Gains Attention As Institutions Expand Exposure

Biomea Fusion (NASDAQ:BMEA) is attracting renewed market interest due to increased institutional investment. The company, a clinical-stage biopharmaceutical firm focusing on precision therapies for cancer and metabolic diseases, sees its outlook driven by clinical execution, regulatory progress, and financial management. Its strategy centers on …

Traws Pharma (TRAW) investor Squadron reports 0% beneficial ownership in 13G/A

Squadron Master Fund LP, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank have filed an amended Schedule 13G (Amendment No. 4) for Traws Pharma (TRAW), reporting 0% beneficial ownership. The group now holds no shares of Traws Pharma common stock and possesses no …

King Street Capital discloses 4.6% Surgery Partners (SGRY) holding in Schedule 13G

King Street Capital Management, L.P., along with King Street Capital Management GP, L.L.C., and Brian J. Higgins, have reported a joint beneficial ownership of 6,058,141 shares of Surgery Partners, Inc. (SGRY) common stock. This holding represents 4.6% of the company's outstanding shares, based on …

Vistagen Therapeutics Releases Q1 2027 Financial Results

Vistagen Therapeutics reported a narrower loss for Q1 fiscal 2027, with a basic and diluted loss of $0.30 per share and a net loss of $13.0M. The company saw a significant revenue increase to $1.5M, up 504.9% year-over-year, as it continues to develop therapies …

Solventum Corp. stock rises Friday, outperforms market

Solventum Corp. (SOLV) stock increased by 2.46% to $88.59 on Friday, marking its third consecutive day of gains. This rise occurred during a generally negative trading session where the S&P 500 Index (SPX) fell 0.17% and the Dow Jones Industrial Average (DJIA) fell 0.20%, …

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth

ANI Pharmaceuticals, Inc. ANIP topped second-quarter earnings and revenue expectations, but the quarter also exposed a softer result for Cortrophin Gel, its key growth driver. That tension matters because Cortrophin now carries more weight in the company's growth mix. ANI kept its broader 2026 …

Elutia Inc. (ELUT): SilverArc Capital reports 4.9% stake in Class A shares

SilverArc Capital Management, LLC and Devesh Gandhi have reported a beneficial ownership of 2,192,980 shares of Elutia Inc. (ELUT) Class A common stock, representing a 4.9% stake. This disclosure, made via an amended Schedule 13G filing, indicates shared voting and dispositive power over these …

Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High‑Risk COVID Market

Pfizer Inc. has completed a real-world study in Korea on Paxlovid, demonstrating its effectiveness in older adults within long-term care hospitals against severe COVID-19, mortality, and decline in daily function. This observational study, which compared Paxlovid users to non-users matched on various factors, supports …

Viatris Inc. stock rises Friday, outperforms market

Viatris Inc. (VTRS) stock increased by 1.18% to $16.23 on Friday, despite a general market downturn where the S&P 500 Index and Dow Jones Industrial Average both saw declines. This gain ended a two-day losing streak for Viatris, indicating a resilient performance against broader …

Why Could Bausch + Lomb (TSX:BLCO) Gain From Aging Demographics?

Steris PLC stock outperforms competitors despite losses on the day

Steris PLC stock (STE) fell 1.18% to $233.28 on Friday, marking its fourth consecutive day of losses. Despite this, the stock outperformed the broader market, as the S&P 500 Index (SPX) dropped 0.17% and the Dow Jones Industrial Average (DJIA) fell 0.20%.

Labcorp Holdings Inc. stock outperforms competitors despite losses on the day

Shares of Labcorp Holdings Inc. (LH) experienced a 1.38% drop on Friday, closing at $318.13. Despite this loss and an overall poor trading day for the stock market, with the S&P 500 and Dow Jones also falling, Labcorp's stock still outperformed its competitors. This …

DYAI: Second Quarter Results

DexCom Inc. stock underperforms Friday when compared to competitors

Shares of DexCom Inc. (DXCM) fell by 1.89% to $89.75 on Friday, underperforming the broader market which saw the S&P 500 Index and Dow Jones Industrial Average also decline. This drop ended a six-day winning streak for the company's stock.

Innate Pharma increases equity bookbuild by a third to €30m

Innate Pharma has increased its equity bookbuild by one-third to €30 million, driven by a new $75 million partnership to develop a lymphoma treatment. The article indicates that this partnership was a significant "catalyst for investors." The full details are available to subscribers of …

Mereo BioPharma (MREO): EcoR1 reports 0.6% passive stake via ADS holdings

EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have reported a passive beneficial ownership of 0.6% each in Mereo BioPharma Group plc. This stake, held through American Depositary Shares (ADS), represents 5,000,000 Ordinary Shares for EcoR1 and Nodelman, and 4,732,750 Ordinary …

Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. has reduced its price target for Oculis (NASDAQ:OCS) to $20.00 from $23.00, while maintaining an "overweight" rating. Despite this reduction and similar cuts by other firms, Oculis still holds a consensus "Moderate Buy" rating with an average price target of …

Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement

Daré Bioscience has announced a definitive securities purchase agreement with institutional investors for a registered direct offering, expecting to raise approximately $6.0 million. The offering includes the sale of about 4.38 million shares of common stock at $1.37 per share, along with concurrent private …

IM Cannabis reports Q2 results

IM Cannabis press release [https://seekingalpha.com/filing/309949813] (IMCC [https://seekingalpha.com/symbol/IMCC]): Q2 revenue of $7.6 million, compared to $12.7 million in the same period in 2025. * Gross profit of $1.5 million, compared to $3.4 million in the same period in 2025. * Operating loss of $2.1 million, …

Lantern Pharma outlines Open Medicine AI spin-out amid $10B market outlook by 2030-2031

Earnings Call Insights: Lantern Pharma (LTRN) Q2 2026 MANAGEMENT VIEW * “In August, we established Open Medicine AI as a separate company with commercial licenses and agreements with Lantern in place to take the AI data models to the next level,” said (President, CEO …

NextCure (NXTC): Squadron funds and partners disclose 1.6% equity stake

Squadron Master Fund LP and its related parties, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, have disclosed a 1.6% equity stake in NextCure, Inc. through a SCHEDULE 13G/A SEC filing. This group beneficially owns 64,464 shares of NextCure common stock and …

Immix Biopharma (NASDAQ:IMMX) Stock Price Down 4.5% - Here's Why

Immix Biopharma (NASDAQ: IMMX) shares dropped 4.5% to $10.43 on Friday, with trading volume significantly below average. This decline followed the company missing its latest quarterly earnings estimate, reporting a loss of $0.18 per share against an expected $0.17 loss. Despite the recent dip, …